NFL ends E.D. drug sponsorship

Share this article:
The NFL decided not to renew its sponsorship agreement with Levitra, which is co-marketed in the U.S. by Schering-Plough and GlaxoSmithKline. The league says it will not seek a replacement in the category, according to published reports. The NFL based its decision on the tone of ads for erectile dysfunction drugs. Over the past three years advertising has ranged in focus from men’s health to men’s performance and lifestyle. Ads by Levitra and others have recently been more restrained, however, not mentioning a product name but describing conditions the drug could help treat.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.